RA CAPITAL MANAGEMENT, L.P. — 13F Holdings & Portfolio
CIK 1346824 · latest 13F-HR filed 2026-08-14
RA CAPITAL MANAGEMENT, L.P. manages $11.51B in 13F-reported U.S. long-equity assets across 85 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ASND (23.83%), PBLS (6.88%), RYTM (6.43%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 17 new positions, exited 18, added to 38, and trimmed 13.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
BOSTON, MA 02116
$11.51B
Long-equity book
85
Distinct positions
2026-06-30
Filed 2026-08-14
+17 / −18 / ↑38 / ↓13
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- RHYTHM PHARMACEUTICALS INC$160.4M +27.7%
- ARTIVA BIOTHERAPEUTICS INC$110.7M +174.5%
- GH RESEARCH PLC$97.3M +90.2%
- BICARA THERAPEUTICS INC$71.1M +49.3%
- CLIMB BIO INC$70.0M +90.4%
Top Trims
- NUVALENT INC-A-$105.7M -40.7%
- TYRA BIOSCIENCES INC-$77.6M -16.6%
- VOR BIOPHARMA INC-$52.2M -54.1%
- GERON CORP-$40.2M -42.3%
- WAVE LIFE SCIENCES LTD-$38.8M -19.9%
New Positions
- ASCENDIS PHARMA A/S$2.74B
- PARABILIS MEDICINES INC$791.9M
- HEMAB THERAPEUTICS HOLDINGS$286.8M
- ABIVAX SA-ADR$150.9M
- ORUKA THERAPEUTICS INC$148.0M
Exited Positions
- ASCENDIS PHARMA A/S - ADR$2.35B
- DIANTHUS THERAPEUTICS INC$219.2M
- PRAXIS PRECISION MEDICINES I$120.4M
- SAREPTA THERAPEUTICS INC$84.9M
- SPYRE THERAPEUTICS INC$81.8M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ASCENDIS PHARMA A/S | ASND | K08588103 | $2.74B | 23.83% | 10,281,496 | SH |
| 2 | PARABILIS MEDICINES INC | PBLS | 698955101 | $791.9M | 6.88% | 28,933,371 | SH |
| 3 | RHYTHM PHARMACEUTICALS INC | RYTM | 76243J105 | $740.2M | 6.43% | 6,666,837 | SH |
| 4 | VAXCYTE INC | PCVX | 92243G108 | $667.0M | 5.80% | 11,474,599 | SH |
| 5 | SIONNA THERAPEUTICS INC | SION | 829401108 | $435.7M | 3.79% | 9,905,045 | SH |
| 6 | TYRA BIOSCIENCES INC | TYRA | 90240B106 | $389.6M | 3.39% | 12,198,625 | SH |
| 7 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $341.0M | 2.96% | 8,392,730 | SH |
| 8 | NEWAMSTERDAM PHARMA CO NV | NAMS | N62509109 | $323.7M | 2.81% | 9,550,191 | SH |
| 9 | HEMAB THERAPEUTICS HOLDINGS | COAG | 423494103 | $286.8M | 2.49% | 7,808,627 | SH |
| 10 | SEPTERNA INC | SEPN | 81734D104 | $234.3M | 2.04% | 6,995,858 | SH |
| 11 | BICARA THERAPEUTICS INC | BCAX | 055477103 | $215.4M | 1.87% | 7,255,993 | SH |
| 12 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $207.6M | 1.80% | 7,692,750 | SH |
| 13 | GH RESEARCH PLC | GHRS | G3855L106 | $205.3M | 1.78% | 7,636,813 | SH |
| 14 | DISC MEDICINE INC | IRON | 254604101 | $179.2M | 1.56% | 2,450,221 | SH |
| 15 | SPYGLASS PHARMA INC | SGP | 85220G109 | $178.6M | 1.55% | 8,021,117 | SH |
| 16 | ARTIVA BIOTHERAPEUTICS INC | ARTV | 04317A107 | $174.2M | 1.51% | 17,955,642 | SH |
| 17 | JANUX THERAPEUTICS INC | JANX | 47103J105 | $171.9M | 1.49% | 11,189,693 | SH |
| 18 | TAYSHA GENE THERAPIES INC | TSHA | 877619106 | $160.4M | 1.39% | 23,555,648 | SH |
| 19 | BIOCRYST PHARMACEUTICALS INC | BCRX | 09058V103 | $158.3M | 1.38% | 15,827,186 | SH |
| 20 | WAVE LIFE SCIENCES LTD | WVE | Y95308105 | $156.7M | 1.36% | 26,975,505 | SH |
| 21 | NUVALENT INC-A | NUVL | 670703107 | $153.9M | 1.34% | 1,246,456 | SH |
| 22 | ABIVAX SA-ADR | ABVX | 00370M103 | $150.9M | 1.31% | 1,132,557 | SH |
| 23 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $148.0M | 1.29% | 1,554,597 | SH |
| 24 | SOLID BIOSCIENCES INC | SLDB | 83422E204 | $120.2M | 1.04% | 12,036,126 | SH |
| 25 | CLIMB BIO INC | CLYM | 28658R106 | $115.0M | 1.00% | 8,821,067 | SH |
| 26 | ZAI LAB LTD-ADR | ZLAB | 98887Q104 | $109.1M | 0.95% | 5,743,533 | SH |
| 27 | ARS PHARMACEUTICALS INC | SPRY | 82835W108 | $87.0M | 0.76% | 10,860,977 | SH |
| 28 | XENCOR INC | XNCR | 98401F105 | $84.9M | 0.74% | 5,274,274 | SH |
| 29 | JADE BIOSCIENCES INC | JBIO | 008064206 | $81.6M | 0.71% | 3,671,083 | SH |
| 30 | INTELLIA THERAPEUTICS INC | NTLA | 45826J105 | $76.6M | 0.67% | 4,526,926 | SH |
| 31 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $71.7M | 0.62% | 2,208,604 | SH |
| 32 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $70.6M | 0.61% | 1,500,000 | SH |
| 33 | ACLARIS THERAPEUTICS INC | ACRS | 00461U105 | $67.3M | 0.58% | 12,723,026 | SH |
| 34 | 4D MOLECULAR THERAPEUTICS IN | FDMT | 35104E100 | $67.2M | 0.58% | 5,049,779 | SH |
| 35 | SANA BIOTECHNOLOGY INC | SANA | 799566104 | $65.4M | 0.57% | 18,750,000 | SH |
| 36 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $62.4M | 0.54% | 2,399,702 | SH |
| 37 | MONOPAR THERAPEUTICS INC | MNPR | 61023L207 | $61.8M | 0.54% | 667,207 | SH |
| 38 | ACUMEN PHARMACEUTICALS INC | ABOS | 00509G209 | $56.1M | 0.49% | 20,992,669 | SH |
| 39 | GERON CORP | GERN | 374163103 | $54.8M | 0.48% | 42,809,751 | SH |
| 40 | REZOLUTE INC | RZLT | 76200L309 | $49.1M | 0.43% | 9,445,039 | SH |
| 41 | EVOMMUNE INC | EVMN | 30054Y107 | $46.4M | 0.40% | 3,494,638 | SH |
| 42 | VOR BIOPHARMA INC | VOR | 929033207 | $44.2M | 0.38% | 2,402,095 | SH |
| 43 | CENTURY THERAPEUTICS INC | IPSC | 15673T100 | $43.5M | 0.38% | 17,754,430 | SH |
| 44 | AKTIS ONCOLOGY INC | AKTS | 01021M104 | $42.4M | 0.37% | 1,314,405 | SH |
| 45 | BIOAGE LABS INC | BIOA | 09077V100 | $41.0M | 0.36% | 1,671,648 | SH |
| 46 | C4 THERAPEUTICS INC | CCCC | 12529R107 | $37.4M | 0.32% | 8,000,000 | SH |
| 47 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $37.3M | 0.32% | 318,554 | SH |
| 48 | CAPRICOR THERAPEUTICS INC | CAPR | 14070B309 | $36.3M | 0.32% | 1,507,844 | SH |
| 49 | PEPGEN INC | PEPG | 713317105 | $36.1M | 0.31% | 20,064,545 | SH |
| 50 | PRELUDE THERAPEUTICS INC | PRLD | 74065P101 | $34.5M | 0.30% | 6,475,882 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $11.51B | 85 | 0001104659-26-097251 |
| 2026-03-31 | 2026-05-15 | $9.44B | 86 | 0001104659-26-062637 |
| 2025-12-31 | 2026-02-17 | $9.76B | 72 | 0001104659-26-016482 |
| 2025-09-30 | 2025-11-14 | $8.12B | 68 | 0001104659-25-112469 |